Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Issue 12 (December 2014)

• Record Type: Journal Article
• Authors: Mark, Tomer M.; Bowman, Isaac A.; Rossi, Adriana C.; Shah, Manan; Rodriguez, Melissa; Quinn, Ryann; Pearse, Roger N.; Zafar, Faiza; Pekle, Karen; Jayabalan, David; Ely, Scott; Coleman, Morton; Chen-Kiang, Selina; Niesvizky, Ruben
• Is Part Of: Leukemia & lymphoma. Volume 55:Issue 12(2014:Dec.)
• Page Start: 2842
• Page End: 2849
• Publication Date: 2014-12
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.896005
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>We studied T-BiRD (thalidomide [Thalomid^®], clarithromycin [Biaxin^®], lenalidomide [Revlimid^®] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1–28; lenalidomide 25 mg/day on days 1–21; and thalidomide 100 mg/day (50 mg/day on days 1–7 of cycle 1 only) on days 1–28. Twenty-six patients received a median of 6 cycles (range 0–41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations.</p> <p>ClinicalTrials.gov identifier: NCT00538733</p> </abstract>